Diplomat Pharmacy, Inc. (NYSE:DPLO)‘s stock had its “buy” rating reaffirmed by equities research analysts at Robert W. Baird in a research note issued to investors on Sunday. They presently have a $20.00 price target on the stock. Robert W. Baird’s price target indicates a potential downside of 1.48% from the stock’s previous close.

A number of other research firms also recently issued reports on DPLO. BidaskClub raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Friday. Bank of America Corporation lifted their target price on Diplomat Pharmacy from $17.00 to $18.50 and gave the company a “neutral” rating in a research report on Thursday, May 25th. TheStreet raised Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research report on Thursday, August 10th. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Finally, Needham & Company LLC assumed coverage on Diplomat Pharmacy in a research report on Friday, July 21st. They issued a “buy” rating and a $19.75 target price on the stock. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $18.66.

Shares of Diplomat Pharmacy (DPLO) opened at 20.30 on Friday. Diplomat Pharmacy has a 1-year low of $12.25 and a 1-year high of $29.65. The company has a market cap of $1.38 billion, a P/E ratio of 110.93 and a beta of 0.65. The stock’s 50 day moving average price is $16.84 and its 200 day moving average price is $16.28.

Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, August 7th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. Diplomat Pharmacy’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.23 earnings per share. Equities research analysts forecast that Diplomat Pharmacy will post $0.75 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Robert W. Baird Reiterates “Buy” Rating for Diplomat Pharmacy, Inc. (DPLO)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/19/robert-w-baird-reiterates-buy-rating-for-diplomat-pharmacy-inc-dplo.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in DPLO. JPMorgan Chase & Co. increased its position in Diplomat Pharmacy by 73.1% during the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock worth $116,000 after buying an additional 3,056 shares during the last quarter. State of Alaska Department of Revenue increased its position in Diplomat Pharmacy by 80.0% during the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock worth $127,000 after buying an additional 3,833 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after buying an additional 2,794 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in Diplomat Pharmacy by 13.8% during the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock worth $142,000 after buying an additional 1,073 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its position in Diplomat Pharmacy by 4.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after buying an additional 480 shares during the last quarter. 69.89% of the stock is currently owned by hedge funds and other institutional investors.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Stock Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related stocks with our FREE daily email newsletter.